Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in Georgia

2364 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Active, closed
Kailera
Phase 3
2,530
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-12-18
Recruiting
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Nevada
2025-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada
2025-12-16
Recruiting
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Recruiting
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Louisiana
2025-12-15
Active, closed
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811Immune System Diseases, Ig-E Mediated Food Allergy
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
110
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Phase 3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2025-12-15
Recruiting
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, New York
2025-12-12
Recruiting
Ascendis Pharma A/S
Phase 3
186
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-11
Recruiting
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
Pfizer
Phase 3
32,500
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2025-12-10
Recruiting
GT Medical Technologies, Inc.
Phase 3
766
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-10
Active, closed
Boehringer Ingelheim
Phase 3
135
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Active, closed
Incyte Corporation
Phase 3
13
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
Ensysce Biosciences
Phase 3
320
Georgia, Texas, Utah
2025-12-09
Active, closed
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-12-03
Recruiting
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2025-12-03
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
Sanofi
Phase 2
37
California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington
2025-12-02
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
By invitation
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
NCT07222605Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
eQ8Health Corporation d/b/a CareONE Concierge
Not applicable
1,000
Georgia
2025-12-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484Type 2 Diabetes, Cortisol Excess
Sparrow Pharmaceuticals
Phase 2
1,500
Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2025-11-29
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
By invitation
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-11-26
Recruiting
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Active, closed
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
Active, closed
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Active, closed
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Recruiting
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
By invitation
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Active, closed
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Arizona, California, Connecticut, Florida, Georgia, Iowa, Kentucky, Louisiana
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2025-11-18
Recruiting
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
NCT07006831Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
Devyser Inc.
Observational
400
California, Georgia, Maryland, Massachusetts, Texas, Utah
2025-11-14
Active, closed
Pfizer
Phase 2
128
Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Recruiting
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Recruiting
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
Mom Multi Postnatal Supplementation Trial
NCT07303595Postnatal Care
Perelel Inc.
Not applicable
80
Georgia
2025-11-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Active, closed
Boston Scientific Corporation
Not applicable
699
Arkansas, California, Georgia, Idaho, New York, Ohio, Pennsylvania, Texas
2025-11-07
Recruiting
Sanofi
Phase 2
208
Arizona, California, Florida, Georgia, Iowa, Louisiana, Missouri, Nevada
2025-11-06
Recruiting
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Pfizer
Phase 1
294
Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
661
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Recruiting
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-11-04
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Oncology, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Recruiting
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Recruiting
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Active, closed
Granata Bio Corporation
Phase 3
659
California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Maryland
2025-11-01
Recruiting
Retension Pharmaceuticals. Inc.
Phase 2
280
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-10-31
Recruiting
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Active, closed
Phathom Pharmaceuticals, Inc.
Phase 2
95
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2025-10-30
Recruiting
Shionogi
Phase 2
45
California, Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Virginia
2025-10-30
Active, closed
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Xenon Pharmaceuticals Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, New Jersey, New York, Pennsylvania
2025-10-30
Active, closed
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
California, Florida, Georgia, Louisiana, Nevada, North Carolina
2025-10-29
Recruiting
Novartis Pharmaceuticals
Phase 3
12
Georgia, New Jersey, Pennsylvania, Tennessee
2025-10-28
Recruiting
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Recruiting
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Alaska, California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Minnesota
2025-10-24
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
AtriCure, Inc.
Not applicable
960
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Recruiting
Boston Scientific Corporation
Not applicable
850
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-10-22
Recruiting
Regeneron Pharmaceuticals
Phase 2
1,200
Alabama, California, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts
2025-10-20
Recruiting
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194Coronary Artery Disease
Orchestra BioMed, Inc
Not applicable
740
Arizona, Florida, Georgia, Indiana, Kansas, Maryland, Massachusetts, Michigan
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
1,196
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-10-20
Recruiting
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
NCT07143669Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Blueprint Medicines Corporation
Observational
750
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana
2025-10-17
Recruiting
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Active, closed
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-10-15
Recruiting
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
Vega Therapeutics, Inc
Phase 3
60
Arkansas, California, Connecticut, Georgia, Michigan, Minnesota, North Carolina, Pennsylvania
2025-10-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
300
California, Connecticut, Florida, Georgia, Maryland, New Jersey, Oklahoma, Pennsylvania
2025-10-09
Recruiting
Sanofi
Phase 1/2
104
Arizona, California, Florida, Georgia, Illinois, Maryland, Nevada, North Carolina
2025-10-09
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
424
Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Alabama, California, Connecticut, Florida, Georgia, Indiana, Maine, Minnesota
2025-10-08
Recruiting
Bristol-Myers Squibb
Observational
223
California, Florida, Georgia, Illinois, Maryland, Michigan, Montana, New Jersey
2025-10-08
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
California, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-06
Recruiting
Pfizer
Phase 2/3
982
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Hawaii
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2025-10-02
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
Active, closed
Study of COYA 302 for the Treatment of ALS
NCT07161999Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics
Phase 2/3
120
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-09-30
Recruiting
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
IVUS CHIP UPP Registry
NCT06625801Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
ECRI bv
Observational
1,010
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota
2025-09-30
Active, closed
AbbVie
Phase 2
84
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2025-09-30
Recruiting
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-09-28
Recruiting
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Recruiting
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-09-26
Active, closed
SPHERE Per-AF Post-Approval Study
NCT06858306Persistent Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alabama, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania
2025-09-25
Recruiting
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-09-25
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Active, closed
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Active, closed
W.L.Gore & Associates
Not applicable
112
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-09-22
Recruiting
Sanofi
Phase 4
218
Alabama, Florida, Georgia, Kansas, Maryland, Massachusetts, North Carolina, Pennsylvania
2025-09-22
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Recruiting
Biometry Inc
Observational
160
California, Florida, Georgia, Maine, Maryland, Nebraska, North Carolina, Ohio
2025-09-17
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-09-17
Recruiting
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
Sanofi
Phase 3
942
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Michigan
2025-09-16
Recruiting
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Texas
2025-09-15
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Recruiting
CSL Behring
Phase 3
200
California, Georgia, Illinois, Kansas, Maryland, New Jersey, New York, Ohio
2025-09-15
By invitation
Iantrek, Inc.
Observational
250
California, Florida, Georgia, Maryland, Nevada, Pennsylvania, Tennessee, Utah
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
414
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-09-13
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
LEO Pharma
Phase 2
135
California, Georgia, Michigan, New York, Ohio, Oregon, Pennsylvania
2025-09-11
Recruiting
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
NCT06784466Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF
Arga Medtech SA
Not applicable
360
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas
2025-09-10
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
NCT07059962Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
Bodyport Inc.
Observational
125
California, Georgia, Illinois, Tennessee
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-09-06
Active, closed
AstraZeneca
Phase 1/2
405
California, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada
2025-09-04
Recruiting
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
By invitation
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Recruiting
Neurocrine Biosciences
Phase 4
100
Arkansas, California, Florida, Georgia, Illinois, Nebraska, Ohio, Texas
2025-08-29
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz North America, Inc.
Phase 3
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-08-27
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, New York, Texas
2025-08-25
Recruiting
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Recruiting
Boston Scientific Corporation
Not applicable
1,616
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
808
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
997
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
Synchrony-Medical, Ltd
Observational
200
Alabama, Georgia, South Carolina
2025-08-20
Recruiting
Hoffmann-La Roche
Phase 2
330
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Montana
2025-08-19
Active, closed
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
Oticon Medical
Observational
25
Georgia
2025-08-15
Recruiting
MapLight Therapeutics
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Louisiana, Nevada, New Jersey
2025-08-15
Recruiting
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
NCT07209475Diabetic Foot Ulcer (DFU), Amnio-Maxx
Royal Biologics
Phase 4
248
California, Florida, Georgia, Nebraska, New York, Oklahoma, Texas
2025-08-14
Recruiting
Abbott Cephea Mitral Valve Disease Registry
NCT07069673Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation
Abbott Medical Devices
Observational
1,000
Alabama, Arizona, California, Georgia, Illinois, Indiana, Kansas, Minnesota
2025-08-13
Recruiting
Tioga Pharmaceuticals
Phase 2
120
Georgia
2025-08-13
Active, closed
Gilead Sciences
Phase 1
16
California, Georgia, Tennessee
2025-08-12
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT07096674Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
90
Alabama, California, Florida, Georgia, Michigan, Nevada, North Carolina, Ohio
2025-08-12
Recruiting
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Ohio
2025-08-11
Active, closed
Novo Nordisk A/S
Phase 3
877
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-08-11
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
400
Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri, Nevada
2025-08-08
Recruiting
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
By invitation
Elumn8 Medical
Not applicable
115
Georgia, Minnesota, New York, Texas
2025-08-06
Recruiting
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Recruiting
Sun Pharmaceutical Industries, Inc.
Phase 3
355
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-08-05
Recruiting
Crystalys Therapeutics
Phase 3
250
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-04
Recruiting
Crystalys Therapeutics
Phase 3
500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
4,390
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Mississippi
2025-07-31
Recruiting
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Recruiting
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Recruiting
Reunion Neuroscience Inc
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
Arizona, Georgia, Iowa, Ohio, Utah, Virginia
2025-07-29
Recruiting
AbbVie
Phase 3
120
Arizona, California, Florida, Georgia, Illinois, New Jersey, Ohio, Pennsylvania
2025-07-28
Recruiting
Optinose US Inc.
Phase 3
84
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kentucky, Maryland
2025-07-28
Recruiting
Reprieve Cardiovascular, Inc
Not applicable
400
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Minnesota
2025-07-28
Recruiting
CSL Behring
Phase 3
20
California, Florida, Georgia, Michigan, Tennessee
2025-07-28
Recruiting
ELEVATE High-Risk PCI Pivotal Study
NCT07001332High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.
Not applicable
290
Arizona, California, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-07-25
Active, closed
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
NCT07146022Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
Veradermics, Inc.
Phase 3
552
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-07-25
Active, closed
Amgen
Phase 3
12,800
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2025-07-25
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-25
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
404
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Not yet open
Asklepion Pharmaceuticals, LLC
Phase 3
120
District of Columbia, Florida, Georgia, Maryland, Michigan, North Carolina
2025-07-25
Recruiting
Pharmazz, Inc.
Phase 3
514
Arizona, California, Florida, Georgia, Missouri, New Jersey, North Carolina, Ohio
2025-07-24
Active, closed
Insmed Gene Therapy LLC
Phase 1
12
Arkansas, California, Georgia, New York, Ohio, Tennessee, Virginia
2025-07-22
Active, closed
Gilead Sciences
Phase 3
339
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Louisiana
2025-07-22
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-07-22
Recruiting
4D Molecular Therapeutics
Phase 3
480
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-07-22
Active, closed
Merz North America, Inc.
Not applicable
30
Georgia
2025-07-22
Active, closed
Compugen Ltd
Phase 1/2
60
Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina, Ohio, Oklahoma
2025-07-21
Recruiting
DualityBio Inc.
Phase 2
750
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
By invitation
Cybin IRL Limited
Phase 3
468
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-07-18
Recruiting
Bristol-Myers Squibb
Phase 3
450
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Active, closed
Daiichi Sankyo
Phase 1
17
California, Georgia, Nevada, North Carolina, Ohio, Tennessee
2025-07-17
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type
Kelonia Therapeutics, Inc.
Phase 1
70
California, Florida, Georgia, Massachusetts, New Jersey, Oregon
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-07-16
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Louisiana, Massachusetts, Michigan
2025-07-15
Recruiting
Takeda
Phase 3
347
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana
2025-07-15
Recruiting
Pfizer
Phase 3
300
California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2025-07-14
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Massachusetts
2025-07-14
Recruiting
Biostar Pharma, Inc.
Phase 2
120
California, Colorado, Georgia, Illinois, Maryland, Nevada, New York, Texas
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Recruiting
Shield Post-Approval Study Protocol
NCT06880055Colo-rectal Cancer
Guardant Health, Inc.
Observational
3,375
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2025-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
409
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-07-11
Recruiting
Neurocrine Biosciences
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Mississippi
2025-07-11
Active, closed
Harbinger Health
Observational
2,450
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana
2025-07-11
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070Heart Transplant, Heart Failure, Transplant; Failure, Heart
XVIVO Perfusion
Not applicable
60
California, Georgia, Illinois, Missouri, Nebraska, New York, North Carolina, Tennessee
2025-07-10
Recruiting
CSL Behring
Phase 2
70
California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-07-10
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT06991114Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
Artiva Biotherapeutics, Inc.
Phase 2
90
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Montana
2025-07-09
Recruiting
ELEVATE-HFpEF Clinical Study
NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
700
Arizona, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-07-09
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
450
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2025-07-08
Recruiting
XyloCor Therapeutics, Inc.
Phase 2
106
Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-07-08
Active, closed
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
Active, closed
Sanofi
Phase 2
105
Alabama, California, Florida, Georgia, Iowa, Massachusetts, Missouri, New York
2025-07-07
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-07-02
Recruiting
Alnylam Pharmaceuticals
Phase 3
2,250
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-02
Active, closed
Upstream Bio Inc.
Phase 2
666
California, Florida, Georgia, Illinois, Maryland, Minnesota, North Carolina, South Carolina
2025-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2025-07-01
Recruiting
Marea Therapeutics
Phase 2
316
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-06-30
Recruiting
Ipsen
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Michigan, New York, Washington
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-06-30
Recruiting
Vektor Medical
Not applicable
423
Arkansas, Florida, Georgia, Indiana, Kentucky, New York, Ohio, Pennsylvania
2025-06-27
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
Kardigan, Inc.
Phase 2/3
1,276
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-27
Recruiting
AstraZeneca
Phase 2
987
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2025-06-27
Recruiting
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
NCT07113522Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
DrugMT-201
Mirador Therapeutics, Inc.
Phase 2
140
Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Illinois, Louisiana
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Amgen
Phase 3
5,056
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2025-06-25
Active, closed
DBV Technologies
Phase 3
480
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-06-24
Active, closed
VK2735 for Weight Management Phase 3
NCT07104500Weight Loss
DrugVK2735
Viking Therapeutics, Inc.
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-06-23
Active, closed
Viking Therapeutics, Inc.
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2025-06-23
Active, closed
Incyte Corporation
Phase 3
580
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
GlaxoSmithKline
Phase 3
961
Alabama, Colorado, Florida, Georgia, Idaho, Illinois, Louisiana, Maine
2025-06-23
Recruiting
Apellis Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
Recruiting
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-06-19
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Arizona, California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts
2025-06-19
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Missouri
2025-06-19
Recruiting
To Assess the Utility of the Point Mini in a Clinical Take-home Study
NCT06501092Amputation; Traumatic, Hand, Amputation, Congenital
Point Designs
Not applicable
14
Colorado, Georgia
2025-06-18
Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NCT06608823Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
JenaValve Technology, Inc.
Not applicable
1,016
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-06-18
Active, closed
AbbVie
Phase 3
573
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-17
Active, closed
Incyte Corporation
Phase 3
159
Alabama, Arizona, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-06-17
Active, closed
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Alpha Tau Medical LTD.
Not applicable
50
Arizona, California, Florida, Georgia, New York, Texas
2025-06-17
Active, closed
An Observational Study of Individuals With Isolated Dystonia
NCT07111663Isolated/Primary Dystonia That Affects More Than One Region of the Body
Vima Therapeutics
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan
2025-06-17
Active, closed
Altimmune, Inc.
Phase 2
121
Arizona, Arkansas, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-06-16
Recruiting
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Florida, Georgia, Illinois, Maryland, Mississippi, Missouri
2025-06-13
Recruiting
Relay Therapeutics, Inc.
Phase 2
277
Arizona, Arkansas, California, Colorado, Georgia, Indiana, Iowa, Maryland
2025-06-13
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Mississippi, New Mexico
2025-06-13
Active, closed
Incyte Corporation
Phase 3
573
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-06-12
Recruiting
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Connecticut, Florida, Georgia, Illinois, New York, Ohio
2025-06-11
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Missouri
2025-06-10
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
AstraZeneca
Phase 3
473
California, Florida, Georgia, Illinois, Louisiana, Nevada, New York, North Carolina
2025-06-10
Recruiting
Celgene
Phase 2
120
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-06-09
Active, closed
Digital Health Navigation Solutions, Inc
Not applicable
6,500
Georgia, North Carolina
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-09
Recruiting
Calico Life Sciences LLC
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Iowa
2025-06-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Massachusetts
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 2
300
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-06-05
Recruiting
Erasca, Inc.
Phase 1
600
California, Colorado, Florida, Georgia, Massachusetts, New York, Texas, Virginia
2025-06-05
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts
2025-06-04
Recruiting
Sanofi
Phase 2
99
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas
2025-06-03
Active, closed
Boston Scientific Corporation
Not applicable
376
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-06-03
Active, closed
Novo Nordisk A/S
Phase 3
609
California, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri
2025-06-03
Recruiting
Novartis Pharmaceuticals
Phase 1/2
30
Arizona, California, Georgia, Pennsylvania, Texas
2025-06-02
Recruiting
Clinical Study of the inQB8 TTVR System (The MonarQ Study)
NCT06611579Tricuspid Valve Regurgitation
inQB8 Medical Technologies, LLC
Not applicable
50
California, Georgia, New York, Pennsylvania, Texas
2025-06-01
Active, closed
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706Atopic Dermatitis, Atopic, Dermatitis, AD
Aclaris Therapeutics, Inc.
Phase 2
110
Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2025-05-30
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals
Phase 3
240
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana
2025-05-30
Active, closed
AstraZeneca
Phase 3
3,103
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-28
Recruiting
Immunovant Sciences GmbH
Phase 3
231
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-05-27
Active, closed
Intuitive Surgical
Observational
200
California, Florida, Georgia, Illinois, Ohio, Texas
2025-05-24
Recruiting
Coologics, Inc
Not applicable
55
Florida, Georgia, Idaho, Illinois, North Carolina, Tennessee, Texas
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Iowa
2025-05-22
Active, closed
Alkermes, Inc.
Phase 2
126
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-05-22
Recruiting
Minima Stent System Post- Approval Study (PAS)
NCT06828770Pulmonary Artery Stenosis, Aortic Coarctation
Renata Medical
Observational
100
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-05-21
Recruiting
Boehringer Ingelheim
Phase 3
4,200
California, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana
2025-05-20
Recruiting
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Concept Medical Inc.
Not applicable
1,605
Arizona, California, Florida, Georgia, Illinois, Mississippi, New Jersey, New York
2025-05-20
Active, closed
Pelacarsen Roll-over Extension Program
NCT06875973Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
599
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-05-19
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Recruiting
Penumbra Inc.
Observational
300
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-05-18
Recruiting
Pfizer
Phase 1
16
District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Ohio, Oklahoma
2025-05-16
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Active, closed
Zura Bio Inc
Phase 2
247
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Massachusetts
2025-05-16
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
CorMedix Therapeutics
Phase 3
200
California, District of Columbia, Florida, Georgia, Illinois, Iowa, Maryland, Minnesota
2025-05-14
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, New York
2025-05-14
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 2
36
California, District of Columbia, Florida, Georgia, Massachusetts, Minnesota, Missouri, North Carolina
2025-05-14
Recruiting
Vanda Pharmaceuticals
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, Mississippi, Missouri, Nevada
2025-05-14
Active, closed
RADIQAL Study (Radiation Dose and Image Quality Trial)
NCT06944509Coronary Artery Disease
Philips Clinical & Medical Affairs Global
Not applicable
824
Colorado, Georgia, New York
2025-05-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-13
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
Eidos Therapeutics, a BridgeBio company
Phase 3
587
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-05-12
Recruiting
Hoffmann-La Roche
Phase 3
425
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-12
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-05-12
Active, closed
OrthoTrophix, Inc
Phase 2
270
Arizona, California, Florida, Georgia, Kansas, Kentucky, Louisiana, Minnesota
2025-05-09
Recruiting
Neurocrine Biosciences
Phase 3
284
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2025-05-08
Recruiting
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Active, closed
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
NCT06907875Facioscapulohumeral Muscular Dystrophy
Epicrispr Biotechnologies, Inc.
Phase 1/2
12
California, Georgia, Maryland, Massachusetts, Utah
2025-05-08
Recruiting
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii
2025-05-06
Recruiting
Takeda
Phase 2
88
Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan
2025-05-06
Active, closed
Hoffmann-La Roche
Phase 2
285
Alabama, California, Florida, Georgia, Illinois, New York, North Carolina, Ohio
2025-05-05
Active, closed
Mediar Therapeutics
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-05
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
59
Connecticut, District of Columbia, Georgia, Michigan, New York, Pennsylvania, South Carolina, Texas
2025-05-01
Not yet open
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
NCT06919796Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
PharmaJet, Inc.
Phase 2
40
Georgia
2025-05-01
Recruiting
SPYRAL GEMINI Pilot Study
NCT06907147Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
175
California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Nevada, New Jersey
2025-05-01
Recruiting
Avvio Medical
Not applicable
101
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Minnesota
2025-05-01
Recruiting
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Recruiting
AbbVie
Phase 2
315
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-04-29
Recruiting
Endevica Bio
Phase 2
120
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Nebraska
2025-04-28
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
SystImmune Inc.
Phase 1
120
Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York
2025-04-28
Active, closed
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-04-24
Recruiting
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Recruiting
Vanda Pharmaceuticals
Phase 3
420
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Montana
2025-04-21
Recruiting
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Recruiting
argenx
Phase 4
35
California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Michigan, Ohio
2025-04-17
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Maryland
2025-04-17
Active, closed
Sanofi
Phase 1/2
720
California, Florida, Georgia, Michigan, Nebraska, Ohio, South Carolina, Texas
2025-04-17
Recruiting
Neurocrine Biosciences
Phase 3
850
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts
2025-04-16
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky, Nebraska
2025-04-16
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa
2025-04-15
Recruiting
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
NCT06893588Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Vesalio
Observational
200
California, Connecticut, Florida, Georgia, Illinois, Iowa, Kentucky, Maine
2025-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Active, closed
Hoffmann-La Roche
Phase 1
56
Arizona, Georgia, Louisiana, Nevada, Tennessee, Texas
2025-04-14
Recruiting
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Kansas
2025-04-09
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
168
Alabama, Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Kansas
2025-04-09
Recruiting
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Active, closed
Hoffmann-La Roche
Phase 2
30
Arkansas, California, Georgia, Michigan, Texas, Virginia
2025-04-04
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Active, closed
Philip Morris Products S.A.
Not applicable
290
Florida, Georgia, Texas
2025-04-02
Active, closed
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, Ohio
2025-04-01
Active, closed
TECTONIC CAD IVL IDE Study
NCT06885177Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Abbott Medical Devices
Not applicable
335
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2025-04-01
Recruiting
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Recruiting
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Missouri
2025-03-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
Recruiting
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
By invitation
Restore Biologics Holdings, Inc. dba Xtressé
Not applicable
60
Florida, Georgia, Maryland, Washington
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
Takeda
Phase 4
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-03-27
Recruiting
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Recruiting
AstraZeneca
Phase 3
600
Arizona, Arkansas, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-03-27
Recruiting
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Boston Scientific Corporation
Observational
1,500
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Illinois
2025-03-26
Recruiting
Gilead Sciences
Phase 2
12
Georgia
2025-03-26
Active, closed
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Active, closed
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Recruiting
Baxis Pharmaceuticals, Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Idaho, Illinois, Maryland, Nevada
2025-03-21
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Recruiting
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Recruiting
Daiichi Sankyo
Phase 3
582
California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts
2025-03-19
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
460
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-03-18
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho
2025-03-16
Active, closed
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Recruiting
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Active, closed
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Active, closed
Celgene
Phase 3
960
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-03-13
Recruiting
Moleculin Biotech, Inc.
Phase 2/3
312
Alabama, Florida, Georgia, Nebraska, New Jersey, Ohio, Pennsylvania, Rhode Island
2025-03-12
Recruiting
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
NCT06915246Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
VIVUS LLC
Phase 2
49
Arizona, California, Georgia, Illinois
2025-03-12
Active, closed
Amgen
Phase 3
3,853
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho
2025-03-12
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Alabama, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2025-03-12
Recruiting
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Active, closed
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264Androgenetic Alopecia, AGA, Male Pattern Baldness
Veradermics, Inc.
Phase 3
480
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-03-11
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Active, closed
Takeda
Phase 3
601
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-03-10
Active, closed
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Alabama, Arizona, California, Florida, Georgia, Kansas, Michigan, New Jersey
2025-03-07
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Active, closed
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-03-06
Active, closed
AstraZeneca
Phase 2
63
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-05
Active, closed
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Recruiting
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Active, closed
Takeda
Phase 3
1,583
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-03
Recruiting
Vanda Pharmaceuticals
Phase 3
500
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-03-03
Active, closed
Voyager Therapeutics
Phase 1/2
52
California, Connecticut, Florida, Georgia, New Jersey, North Carolina, Pennsylvania
2025-03-03
Active, closed
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics
Phase 3
480
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Recruiting
Incyte Corporation
Phase 3
600
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-28
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
538
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland, New Jersey
2025-02-28
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,268
California, Florida, Georgia, Iowa, Kentucky, Mississippi, Nebraska, New York
2025-02-28
Active, closed
Adverum Biotechnologies, Inc.
Phase 3
311
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-02-28
Active, closed
Sanofi
Phase 2
84
Georgia, Michigan, Texas, Utah
2025-02-28
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Hansoh BioMedical R&D Company
Phase 1
631
Florida, Georgia, Indiana, North Carolina, Texas, Virginia
2025-02-26
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
Pacira Pharmaceuticals, Inc
Phase 2
135
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-02-26
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-02-24
Recruiting
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
By invitation
Axsome Therapeutics, Inc.
Phase 3
236
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2025-02-20
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH
Phase 2
56
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts
2025-02-19
Active, closed
Sanofi
Phase 3
2,360
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-02-18
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Lighthouse Pharmaceuticals, Inc.
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana, Maryland
2025-02-17
Recruiting
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Recruiting
OurRelationship
Not applicable
120
Georgia, Maryland, New York, South Carolina, Texas
2025-02-15
Active, closed
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Active, closed
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd
Phase 2
100
California, Florida, Georgia, Maryland, Oregon, Pennsylvania, Virginia
2025-02-11
Recruiting
AbbVie
Phase 3
130
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2025-02-11
Recruiting
Neuraptive Therapeutics Inc.
Phase 3
98
California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-02-10
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Active, closed
Genmab
Phase 3
584
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Phase 1/2
108
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Michigan
2025-02-06
Recruiting
Maze Therapeutics
Phase 2
74
Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2025-02-05
Recruiting
LEO Pharma
Phase 3
90
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-02-05
Active, closed
Annovis Bio Inc.
Phase 3
861
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-02-04
Recruiting
BioNTech SE
Phase 3
621
Arizona, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana
2025-02-03
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-02-03
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2025-02-03
Recruiting
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527Rotator Cuff Tears of the Shoulder
Anika Therapeutics, Inc.
Not applicable
150
Arizona, California, Florida, Georgia, Indiana, Maryland, New Jersey, South Carolina
2025-02-01
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Active, closed
Boehringer Ingelheim
Phase 2
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-31
Recruiting
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Recruiting
Buzzard Pharmaceuticals
Phase 2
20
California, Georgia
2025-01-30
Active, closed
Definium Therapeutics US, Inc.
Phase 3
245
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, New Jersey, Ohio
2025-01-29
Recruiting
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Alkermes, Inc.
Phase 2/3
786
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-27
By invitation
Verismo Therapeutics
Observational
60
Colorado, Georgia, Kansas, New Jersey, Pennsylvania, Texas, Wisconsin
2025-01-27
Recruiting
Incyte Corporation
Phase 3
180
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-01-24
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
United Therapeutics
Observational
900
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-23
Active, closed
Astellas Pharma Global Development, Inc.
Observational
488
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2025-01-22
Recruiting
Incyte Corporation
Phase 3
240
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-21
Recruiting
AbbVie
Phase 2
150
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-01-20
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-01-17
Active, closed
argenx
Phase 3
631
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-15
Recruiting
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Recruiting
Immatics US, Inc.
Phase 3
450
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2025-01-14
Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551Degenerative Disc Disease (DDD)
ReGelTec, Inc.
Not applicable
225
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kansas, Louisiana
2025-01-13
Recruiting
Collagen Matrix
Observational
118
Georgia, Massachusetts
2025-01-13
Recruiting
Laminate Medical Technologies
Not applicable
300
California, Florida, Georgia, Louisiana, Massachusetts, Mississippi, Nevada, South Carolina
2025-01-13
Active, closed
Mylan Pharmaceuticals Inc
Phase 3
1,630
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky
2025-01-13
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-01-10
Recruiting
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Recruiting
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
Novo Nordisk A/S
Phase 3
480
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-01-10
Recruiting
Pan-tumor MRD Study
NCT06605404Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer)
Paradigm Health
Observational
1,350
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-08
Recruiting
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Active, closed
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Active, closed
Pfizer
Phase 3
1,037
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky, Maryland
2025-01-03
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1
158
Arizona, California, Florida, Georgia, Illinois, Michigan, Minnesota, New York
2024-12-30
Active, closed
AstraZeneca
Phase 1/2
242
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
248
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Michigan
2024-12-23
Active, closed
Coherus Oncology, Inc.
Phase 2
72
Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky, Mississippi
2024-12-20
Active, closed
Merck Sharp & Dohme LLC
Phase 1
72
Florida, Georgia, Missouri, Tennessee
2024-12-20
Recruiting
Sanofi
Phase 2
84
Alabama, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nevada
2024-12-19
Recruiting
Cytokinetics
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-12-19
Active, closed
Vertex Pharmaceuticals Incorporated
Observational
401
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2024-12-19
Active, closed
Celldex Therapeutics
Phase 2
131
Alabama, California, Florida, Georgia, Idaho, Illinois, Kentucky, Michigan
2024-12-18
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
455
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-18
Active, closed
Asahi Kasei Therapeutics, AB
Phase 4
60
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky
2024-12-17
Rows per page Showing 501–1000 of 2364
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,364 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,225 of the 2,364 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 32 have not yet opened recruitment, 1,047 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.